Evommune (EVMN) Revenue & Revenue Breakdown
Evommune Revenue Highlights
Latest Revenue (Y)
$7.00M
Evommune Revenue by Period
Evommune Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $7.00M | 40.00% |
| 2023-12-31 | $5.00M | - |
Evommune generated $7.00M in revenue during NA 2024, up 40.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Evommune Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | -100.00% |
| 2025-03-31 | $3.00M | 100.00% |
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $7.00M | - |
Evommune generated - in revenue during Q2 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Evommune Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FTRE | Fortrea | $2.72B | $701.30M |
| LGND | Ligand Pharmaceuticals | $268.09M | $115.46M |
| GLPG | Galapagos | $239.70M | $62.43M |
| KPTI | Karyopharm Therapeutics | $146.07M | $44.04M |
| CDXS | Codexis | $70.39M | $8.60M |
| EYPT | EyePoint Pharmaceuticals | $31.37M | $966.00K |
| OABI | OmniAb | $18.67M | $2.24M |
| EVMN | Evommune | $7.00M | - |
| ARTV | Artiva Biotherapeutics | - | - |
| CLYM | Climb Bio | - | - |
| ZYME | Zymeworks | $-27.11M | $48.73M |